 Featured News June 16, 2008
Med BioGene Expands Lymphoma Collaboration; Becomes Founding Corporate Collaborator of Translational Working Group in Hematologic Malignancies
May 29, 2008
Med BioGene Appoints Diagnostics Industry Veteran Dr. Heiner Dreismann to Board of Directors
April 23, 2008
Med BioGene and University Health Network Collaborate to Commercialize Critical Lung Cancer Prognostic Test
| Welcome to Med BioGene Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic and screening tests for cancer and cardiovascular disease. MBI’s lead products are LungExpress Dx™, a gene expression-based prognostic test for lung cancer, and LymphExpress Dx™, a gene expression-based diagnostic and prognostic test for lymphoma.  A Message From Our CEO
Med BioGene Appoints Diagnostics Industry Veteran Dr. Heiner Dreismann
read more
|
E-MAIL ALERTS
Subscribe to our e-mail news alerts
Quick Facts
Download our facts sheet
|
Home 
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer